News

Dermagnostix has been selected for the prestigious MedTech Innovator (MTI) 2026 Accelerator Cohort, placing the company among the top 4% of medtech startups worldwide.

Dermagnostix GmbH is launching the PE-TargetDisk (RUO), an innovative solution for dermatology practices. The disk enables rapid molecular measurements at the gene expression level directly on-site, without shipping samples and without long wait times.

Das MedTech-Unternehmen Dermagnostix, Spezialist für vollautomatisierte Plug-and-Play Molekulardiagnostik in der Dermatologie, wird im Bereich der molekularen Diagnostik von Hauterkrankungen künftig mit Euroimmun, weltweit führender Anbieter von Testsystemen zur medizinischen Labordiagnostik zusammenarbeiten. Beide Unternehmen sind Vorreiter auf diesem Gebiet und bündeln nun ihr Fachwissen, um molekulare Anwendungen großflächig in der dermatologischen Routinediagnostik zu etablieren.

Dermagnostix announces the launch of the TargetDisk product line, expanding its portfolio with innovative molecular research tools designed for dermatological studies. The TargetDisk line represents the company’s new research portfolio, developed to support researchers in exploring the molecular mechanisms of the skin.

This week, Vienna became the meeting point for pathologists from all over the world at the 37th European Congress of Pathology. For Dermagnostix, it was an inspiring opportunity to connect with experts, exchange ideas, and shine a spotlight on our passion: molecular diagnostics in dermatopathology. We were especially excited to join the very first Joint European Meeting of […]

Freiburg/Baden-Dättwil (CH), 1 September 2025 – Dermagnostix, specialized in the development of molecular diagnostic tests for dermatological issues, starts its distribution partnership with Axon Lab AG on 1 September 2025. For over 35 years, Axon Lab AG has been combining innovative technology, knowledge, and ideas to provide personalized services that create added value for professionals and […]

Our CEO had the honor of being the special guest on the JuDerm podcast. In episode 13, they discussed the importance of implementing molecular diagnosis in patients today and how certain methods can facilitate the work of dermatologists, thereby ensuring an accurate diagnosis, which is essential for determining the appropriate therapies for each patient and […]

Freiburg im Breisgau, 05.05.2025 – The Dermagnostix GmbH from Freiburg, specialized on the development of molecular diagnostic tests for dermatology, expands its portfolio by the acquisition and continuation of the fluorescence detector technology of Dialunox GmbH i.L. (Stockach) as of July 1st 2025. Following the acquisition of facilities, expertise and IP rights from (former) Spindiag […]

Freiburg im Breisgau, 05.05.2025 – Die Dermagnostix GmbH aus Freiburg, spezialisiert auf die Entwicklung molekulardiagnostischer Tests für dermatologische Fragestellungen, erweitert ihr Leistungsportfolio durch die Übernahme und Fortführung der Fluoreszenzdetektor Technologie der Dialunox GmbH i.L. aus Stockach zum 01.07.2025. Die Dermagnostix GmbH unternimmt nach Übernahme von Räumlichkeiten, Knowhow und IP-Rechten von der (ehemals) Spindiag GmbH im […]

Dermagnostix CEO and Co-founder Prof. Dr. Natalie Garzorz Stark has been awared the Innovation Award Dermatology by Bundesverband der Deutschen Dermatologen (BVDD) e.V. The BVDD Innovation Award is an annual competition honoring innovative approaches that enhance dermatological practice and patient care. Recognized projects include innovative patient care models, advancements in dermatological prevention, new diagnostic and […]